13F-HR/A filed by Decheng Capital Management III (Cayman), LLC
Decheng Capital Management III (Cayman), LLC filed this 13F-HR/A for the quarter ended 2023-09-30, filed 2023-11-29, with 27 holding rows worth $312,948,514.
- Accession
- 0001104659-23-122012
- Filer
- CIK 1747821
- Filed
- 2023-11-29
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2023
A holdings report, amendment of type restatement, 27 entries on the cover page, a total value of $312,948,514 stated on the cover page (in dollars after the unit check, H1), rows summing to $312,948,514 with VALUE read as dollars as filed, 13F file number 028-22474. A later restatement replaced it, so the quarter does not use it. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 6,708,288 | $76,809,898 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 2,099,583 | $42,117,635 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 1,163,123 | $18,243,928 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 1,459,700 | $17,049,296 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 1,548,317 | $15,746,384 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 869,790 | $15,612,731 | dollars as filed | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 359,554 | $14,831,603 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 27,429 | $13,484,919 | dollars as filed | |
| NOVABRIDGE BIOSCIENCES | 44975P103 | CMN | 4,166,667 | $13,313,230 | dollars as filed | |
| PACIFIC BIOSCIENCES CALIF INC COM | 69404D108 | Stock | 1,463,872 | $12,223,331 | dollars as filed | |
| ILLUMINA INC | 452327109 | COM | 80,859 | $11,100,324 | dollars as filed | |
| LANTHEUS HLDGS INC | 516544103 | COM | 142,196 | $9,879,778 | dollars as filed | |
| HORIZON THERAPEUTICS PLC | G46188101 | SHS | 78,900 | $9,127,941 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 850,000 | $8,814,500 | dollars as filed | |
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 415,880 | $6,600,016 | dollars as filed | |
| SEAGEN INC | 81181C104 | COM | 23,014 | $4,882,420 | dollars as filed | |
| CUE HEALTH INC | 229790100 | COM | 8,980,909 | $3,969,798 | dollars as filed | |
| BEYONDSPRING INC | G10830100 | SHS | 4,958,143 | $3,966,514 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 714,285 | $3,592,854 | dollars as filed | |
| EQUILLIUM INC | 29446K106 | COM | 4,447,308 | $3,291,008 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 526,329 | $2,547,432 | dollars as filed | |
| ATRICURE INC | 04963C209 | COM | 46,259 | $2,026,144 | dollars as filed | |
| SCYNEXIS INC | 811292200 | COM NEW | 555,555 | $1,266,665 | dollars as filed | |
| Mersana Therapeutics Inc | 59045L106 | Common Stock | 904,268 | $1,148,420 | dollars as filed | |
| PYXIS ONCOLOGY INC COMMON STOCK | 747324101 | Stock | 326,810 | $650,352 | dollars as filed | |
| GENEDX HOLDINGS CORP | 81663L200 | COM CL A | 103,604 | $377,118 | dollars as filed | |
| ADICET BIO INC | 007002108 | COM | 200,201 | $274,275 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-23-117065 | superseded | 2023-11-13 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-23-122012 | this filing | 2023-11-29 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-23-125265 | base | 2023-12-12 | acceptance time not in the bulk data set |